Literature DB >> 15162819

Management of intraocular retinoblastoma and ocular prognosis.

Shigenobu Suzuki1, Akihiro Kaneko.   

Abstract

Current management modalities for intraocular retinoblastoma, their indications, and ocular prognosis are reviewed. Enucleation, external beam radiotherapy, plaque radiotherapy, laser photocoagulation and hyperthermia, and cryotherapy are the modalities generally employed. Recently, neoadjuvant chemotherapy has been introduced for retinoblastoma to avoid external beam radiotherapy. New treatment modalities such as subconjunctival injection, selective ophthalmic artery injection, and vitreous injection are being investigated and have achieved favorable results. Although many modalities are employed, almost half of retinoblastoma eyes have to be enucleated. New treatment modalities are expected.

Entities:  

Mesh:

Year:  2004        PMID: 15162819     DOI: 10.1007/s10147-003-0366-0

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  19 in total

1.  Selective ophthalmic arterial injection of melphalan for intraocular retinoblastoma: a 4-year review.

Authors:  Sherine Jue Ong; An-Ning Chao; Ho-Fai Wong; Kuan-Lyin Liou; Ling-Yuh Kao
Journal:  Jpn J Ophthalmol       Date:  2014-12-03       Impact factor: 2.447

Review 2.  Management of retinoblastoma in children: current status.

Authors:  Guillermo Chantada; Paula Schaiquevich
Journal:  Paediatr Drugs       Date:  2015-06       Impact factor: 3.022

3.  T1 Gd-enhanced compared with CISS sequences in retinoblastoma: superiority of T1 sequences in evaluation of tumour extension.

Authors:  Elke R Gizewski; Isabel Wanke; Christine Jurklies; Ali-Riza Güngör; Michael Forsting
Journal:  Neuroradiology       Date:  2005-01-14       Impact factor: 2.804

4.  Enucleation for retinoblastoma: the experience of a single center in Jordan.

Authors:  Iyad Sultan; Matthew W Wilson; Ibrahim Nawaiseh; Mustafa Mehyar; Saamir Kharma; Mohammed Al-Qudimat; Ribhi Hazin; Arwa Alalami; Imad Jaradat; Maysa Al-Husseini; Ghadeer Abdeen; Carlos Rodriguez-Galindo; Ibrahim Qaddoumi
Journal:  Int Ophthalmol       Date:  2010-04-28       Impact factor: 2.031

Review 5.  Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma.

Authors:  Eleanor M Pritchard; Michael A Dyer; R Kiplin Guy
Journal:  Mini Rev Med Chem       Date:  2016       Impact factor: 3.862

6.  Genome-wide changes accompanying the knockdown of Ep-CAM in retinoblastoma.

Authors:  Moutushy Mitra; Mallikarjuna Kandalam; Rama Shanker Verma; Krishnan UmaMaheswari; Subramanian Krishnakumar
Journal:  Mol Vis       Date:  2010-05-11       Impact factor: 2.367

7.  Clinical results of chemotherapy based treatment in retinoblastoma patients: a single center experience.

Authors:  Hyery Kim; Ji Won Lee; Hyoung Jin Kang; Hyeon Jin Park; Yoon Yi Kim; Hee Young Shin; Young Suk Yu; Il Han Kim; Hyo Seop Ahn
Journal:  Cancer Res Treat       Date:  2008-12-31       Impact factor: 4.679

8.  [Retinoblastoma].

Authors:  N Bornfeld; D Lohmann; N E Bechrakis; E Biewald
Journal:  Ophthalmologe       Date:  2020-04       Impact factor: 1.059

9.  Persistence of retinal function after selective ophthalmic artery chemotherapy infusion for retinoblastoma.

Authors:  Scott E Brodie; Y Pierre Gobin; Ira J Dunkel; Jonathan W Kim; David H Abramson
Journal:  Doc Ophthalmol       Date:  2009-01-25       Impact factor: 2.379

10.  Current therapy and recent advances in the management of retinoblastoma.

Authors:  Rachna Meel; Venkatraman Radhakrishnan; Sameer Bakhshi
Journal:  Indian J Med Paediatr Oncol       Date:  2012-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.